Study Evaluating Premarin and Bazedoxifene Potential Interaction

Phase 1 Completed 30 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (absorption, distribution, breakdown and elimination in the body) of a single dose of bazedoxifene (BZA) 20 mg tablet when administered together with multiple doses of Premarin (conjugated estrogens or CE) to healthy postmenopausal women. Information will also be obtained regarding the safety and tolerability of this combination in healthy, postmenopausal women.

Timeline

Start: 2008-09
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	conjugated estrogens	Other / unclassified	—	—

Indications

No indication recorded.